SequelSEC

SELLAS Life Sciences Group, Inc. SLS

Pharmaceutical Preparations · CIK 0001390478 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$37.87M
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 and net income of -$37.34M for the fiscal year ended 2023-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from SELLAS Life Sciences Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SELLAS Life Sciences Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Revenue$0$1.00M$7.60M$1.90M$0$9.32M
Cost of revenue$0$100.00K$200.00K$0Unavailable$1.40M
Gross profitUnavailable$900.00K$7.40M$1.90MUnavailable$7.92M
Operating income-$37.87M-$41.95M-$25.29M-$16.98M-$20.04M-$43.90M
Net income-$37.34M-$41.30M-$20.70M-$16.76M-$19.29M-$36.61M
Research & developmentUnavailableUnavailable$15.67M$9.28M$7.28MUnavailable
Weighted-average diluted sharesshares 27.78Mshares 19.40Mshares 15.48Mshares 7.98MUnavailableUnavailable
Pretax income-$37.34M-$41.30M-$20.94M-$16.77M-$19.37M-$28.28M
Income tax expense$0$0-$237.00K-$17.00K-$81.00K$0
Diluted EPS$-1.34$-2.13$-1.34$-2.11UnavailableUnavailable
Selling, general & administrative$13.86M$12.58M$11.32M$9.60M$9.92MUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SELLAS Life Sciences Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Cash & equivalents$2.53M$17.12M$21.36M$35.30M$7.28M$23.65M
Total assets$6.22M$20.94M$26.28M$46.05M$16.61M$80.49M
Current assets$3.17M$17.76M$23.04M$36.92M$8.24M$52.10M
Total liabilities$14.20M$16.09M$5.93M$18.09M$10.52M$43.43M
Current liabilities$13.74M$15.52M$4.98M$12.34M$5.29M$27.23M
Total equity incl. NCI-$7.98M$4.85M$20.35M$27.96M$6.09M$37.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable$655.00K
Accounts receivableUnavailableUnavailable$0UnavailableUnavailable$1.84M
Goodwill$1.91M$1.91M$1.91M$1.91M$1.91M$5.90M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable$4.49M
Accounts payable$5.64M$3.36M$2.14M$4.66M$3.90M$1.89M

Cash flow

SELLAS Life Sciences Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Operating cash flow-$31.41M-$23.81M-$26.02M-$10.42M-$17.64M-$42.87M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable$57.00K
Investing cash flow-$5.50M-$4.50M$0UnavailableUnavailable-$5.53M
Financing cash flow$22.32M$24.08M$12.07M$38.44M$19.57M$24.26M
Net change in cash-$14.60M-$4.23M-$13.95M$28.02M$1.93M-$24.14M
Stock-based compensation$2.09M$1.73M$1.01M$578.00K$573.00K$4.67M
Common dividends paidUnavailableUnavailableUnavailableUnavailable$0Unavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable$86.00K

Derived

SELLAS Life Sciences Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-312014-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable-$42.93M
Gross marginUnavailable90.0%97.4%100.0%Unavailable84.9%
Operating marginUnavailable-4195.0%-332.8%-893.8%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailable172.6%13.3%30.4%UnavailableUnavailable
Current ratio0.23x1.14x4.63x2.99x1.56x1.91x
Revenue YoY growth-100.0%-86.8%300.0%UnavailableUnavailableUnavailable
Net marginUnavailable-4130.1%-272.4%-881.9%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable488.5%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SLS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.